Dr Harry Erba presents data from the the QuANTUM-First international, randomised, double-blind, placebo-controlled phase 3 study during a press conference at the EHA 2022 meeting.

The study sought to determine whether the addition of quizartinib to standard induction and post-remission consolidation therapy followed by single-agent continuation of quizartinib for up to three years improved overall survival in patients with newly diagnosed FLT3-ITD positive AML.

Watch our interview with Dr Erba here

Read the news story here